Vitrakvi (Larotrectinib) for Melanoma

Overview
Vitrakvi is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat children and adults with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic (have spread), can’t be removed with surgery, have no other satisfactory treatments, or progressed after treatment. Vitrakvi is also known by its drug name, larotrectinib. 

Vitrakvi belongs to a class of drugs called kinase inhibitors. Vitravki works by blocking the action of an abnormal protein that signals cancer cells to multiply, thus stopping or slowing their growth.

How do I take it?
Prescribing information states that Vitrakvi is taken orally (by mouth) twice daily as a capsule or a solution.

Vitrakvi should be taken exactly as prescribed by a doctor.

Side effects
Common side effects of Vitrakvi include nausea, vomiting, diarrhea, constipation, abdominal pain, cough, dizziness, tiredness, fever, muscle and bone pain, and abnormal blood tests. 

Serious side effects include nerve damage, fractures, liver problems, and fetal harm.

For more details about this treatment, visit:

Vitrakvi (Larotrectinib) — BayerVitrakvi — Drugs.com